ABSTRACT – BSL-3 Practices Core (Core 2)
The central mission of the Regional Biocontainment Laboratory Network is to provide a location and an
environment in which groundbreaking research on potentially dangerous pathogens can be performed safely.
As anyone with the responsibility of managing a leading BSL-3/ABSL-3 facility such as the Duke RBL will
attest, it is critical to imbue a culture of safety in which all individuals seek continuous improvement and
refinement of best practices. This culture of constant improvement must be sustained through the inevitable
turnover of staff that occurs in any long-standing facility, and while it is difficult to codify, we pride ourselves on
providing a cordial and supportive environment in which ideas for improvement by all members of the team are
welcomed. Viewed through this lens, the practices and Standard Operating Procedures (SOPs) that define the
Duke RBL are continuously being refined and improved. Since the opening of the facility in 2007, the Duke
RBL has led the field with a world class safety team dedicated to providing safe, secure, and compliant
research through managing SOPs, conducting a rigorous training program, and assessments of performance.
Support from this grant will allow for the further enhancement of these programs through warm-readiness and
additional dedicated safety staff. Specific aims for this proposal are to 1) establish and maintain procedures for
safe and compliant research at BSL-3/ABSL-3; 2) provide biosafety theory education with hands-on instruction
for all personnel entering BSL-3/ABSL-3 for work with Select Agents; and 3) ensure continuous compliance
with established procedures by conducting routing biosafety/security audits and drills. The ability to maintain
and expand these robust safety programs to account for novel pathogens is critical for investigators to
adequately prepare for the next pandemic.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2019-nCoVAlpha VirusAnimal ModelApplied ResearchAreaBasic ScienceBiologicalBiological AssayCellular AssayCertificationContainmentCoronavirusCytomegalovirusDangerousnessDedicationsDiagnosticEbolaEducationEmerging infectionEnsureEnvironmentEquipment and supply inventoriesFee-for-Service PlansFerretsFlavivirusFundingGrantHIVHamstersHeartHemagglutinationHomeHumanHuman ResourcesImmune responseImmunologyIn VitroIndividualInfluenzaLaboratoriesLocationMalariaMicrobiologyMissionMolecularMusMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseaseOryctolagus cuniculusPerformancePharmaceutical PreparationsPoxviridaeProceduresProteinsProtocols documentationPublicationsReadinessResearchResearch DesignResearch PersonnelResearch SupportResource DevelopmentRouteSafetySecureSecuritySerologyServicesSiteSocietiesTherapeuticTimeTrainingTraining ActivityTraining ProgramsTraining SupportTranslational ResearchTuberculosisUnited States National Institutes of HealthUniversitiesVaccinesViral Load resultVirusWorkWorkforce DevelopmentYersinia pestisZIKAanimal imagingbiocontainment facilitybiodefensebiosecuritydesignemerging pathogenexperiencefuture pandemicglobal healthhands on instructionimmune reconstitutionimprovedin vivoinfluenzavirusinstrumentationlensmembermultiplex assaynovel vaccinesoperationpathogenprogramssquare footsupportive environmenttheoriesvirology
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
044387793
UEI
TP7EK8DZV6N5
Project Start Date
18-August-2023
Project End Date
31-July-2028
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$895,157
Direct Costs
$555,998
Indirect Costs
$339,159
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$895,157
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UC7AI180254-02 9672
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UC7AI180254-02 9672
Patents
No Patents information available for 5UC7AI180254-02 9672
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UC7AI180254-02 9672
Clinical Studies
No Clinical Studies information available for 5UC7AI180254-02 9672
News and More
Related News Releases
No news release information available for 5UC7AI180254-02 9672
History
No Historical information available for 5UC7AI180254-02 9672
Similar Projects
No Similar Projects information available for 5UC7AI180254-02 9672